Meta-analyses of these trials have shown the benefits of the use of SGLT2 inhibitors and GLP1-RA in type 2 diabetic patients at high risk of ASCVD or established ASCVD, as well as in heart failure patients with reduced ejection fraction with the former class of medication [9,10]. The gene discussed is SLC5A2; the disease is atherosclerosis.